Background: Intravascular hemolysis and in vitro hemolysis are prevalent contributors to failed blood sample analysis in the routine hospital laboratory. Interferences by hemoglobin in spectrophotometric and certain enzyme activity assays is the major causative factor. Methods: By exploiting the hemoglobin-binding properties of the iron-regulated surface determinant H (IsdH) protein from Staphylococcus aureus we have developed a new method to instantly remove hemoglobin and hemoglobin-haptoglobin complexes from plasma in vitro thereby enabling the measurement of hemoglobin-sensitive analytes in hemolyzed plasma. In the present study we used an engineered IsdH mutant form conjugated to Sepharose for the efficient removal of plasma hemoglobin in concentrations up to 15 mg/mL. The high abundance of haptoglobin, which forms a tight complex with hemoglobin in plasma, did not affect the hemoglobin removal by IsdH Sepharose. Results: Applying the method on plasma samples that beforehand were spiked with blood hemolysate re-enabled measurement of the hemolysis sensitive parameters: alkaline phosphatase, conjugated bilirubin, iron, ferritin, γ-glutamyltransferase, total thyroxine and troponin T. IsdH Sepharose-mediated hemoglobin removal also enabled measurement of hemolysis sensitive parameters in hemolyzed samples from anonymized patients.
Introduction
A common cause of erroneous laboratory results, that may hamper a fast and correct diagnosis, is the interference from pre-analytical factors, chief among these is hemolysis [1] . Multiple diseases of infectious, genetic, immunological or toxic origin may cause in vivo hemolysis, but most often hemolysis in blood samples is caused by the venipuncture process or preanalytical steps, e.g. the most frequent source is sample collection and far less are storage, transportation or centrifugation [2] [3] [4] .
Estimates of the ratio of hemolyzed plasma samples in routine blood analysis varies but figures ranging from 1% to 3% are reported in the literature, and some reports even state 12% [4] [5] [6] [7] . Overall, hemolysis is the causative factor of 40%-70% of all routine samples deemed unsuitable for correct analysis [4] .
Many assays performed in a routine clinical biochemistry laboratory relies on colorimetric measurements for the detection and quantification of the analyte in serum or plasma. The absorption of hemoglobin (Hb) in the redband area interferes with and compromises the absorbance measurements [4] . In addition, Hb inhibits several enzymes thereby interfering with assays for measurements [4] . More problems of hemolysis are not caused by Hb itself: cellular release of measured analytes from erythrocytes, white blood cells and platelets may falsely elevate the analyte concentration and extracellular analytes may be diluted due to cellular release, and the removal of Hb may not enable correction for those effects [8, 9] . Amongst the assays sensitive to the color interference from Hb contamination are: conjugated bilirubin (BILI-C), creatine kinase (CK), iron (Fe), ferritin [10] , γ-glutamyltransferase (GGT), pancreatic amylase (AmylP), troponin T (TnT), alkaline phosphatase (ALP) and total thyroxine (TT4) [4, 11] .
The degree of hemolysis is measured by the so-called hemolytic index (H-index), which is a spectrophotometric measurement of the Hb concentration performed routinely in many high-throughput routine laboratories. The effects of hemolysis on the measurement of blood parameters may occur from H-indices below the visual detection limit of 0.3 mg/mL Hb for the most sensitive assays corresponding to lysis of only 0.5% erythrocytes in a blood sample [4] .
Haptoglobin (Hp) is an abundant plasma protein that binds Hb with a very high affinity and thereby functions as a first line of defense against hemoglobin toxicity. Concordantly, in a hemolyzed plasma sample Hb is found in a complex with Hp up to the point where the Hb concentration exceeds the Hp binding capacity of 0.3-1.8 mg/mL Hb [12, 13] . Thus, when clearing Hb from plasma it is essential also to remove the pool of Hb bound to Hp. During in vivo hemolysis, complexes of Hb and Hp are rapidly removed by the receptor CD163 expressed on macrophages [14] thereby depleting Hp from plasma. In contrast the Hb-Hp complex is not removed if hemolysis happens in vitro [13] and the presence of Hp therefore indicates that hemolysis in a blood sample is an in vitro event.
Here, we present a technology where we use the bacterial protein IsdH (which stands for iron-regulated surface determinant H) for capturing Hb to Sepharose beads. The protein IsdH is a part of the iron-regulated surface determinant (Isd) system of Staphylococcus aureus, where it is anchored to the cell surface binding Hb or the Hb-Hp complex during blood infections enabling the bacteria to sequester iron from the host [15, 16] . The protein consists of three near-iron transporter (NEAT) domains: NEAT domain 1 and 2 (N1 and N2) anchor Hb to IsdH, while N3 extracts the heme group [17, 18] and passes it on to IsdA and IsdC in the cell wall, followed by transport over the cell membrane by the IsdEF complex. Subsequently, iron is extracted from heme and used by the bacterium (reviewed in [19] ).
In the present study we have modified IsdH by adding a C-terminal cysteine enabling site-specific conjugation to thiopropyl Sepharose beads and by introducing the amino acid substitution Y642A in the N3 domain to prevent heme extraction. This IsdH variant is designated IsdH-C. Like the native IsdH protein, IsdH-C is easily expressed in high yield in a bacterial expression system [16] making it suitable for use as a reagent for binding large amounts of Hb. In this paper we describe how coupling of IsdH-C to Sepharose beads allows efficient removal of large amounts of Hb from hemolyzed plasma samples by a simple centrifugation step, enabling the analysis of a range of parameters otherwise precluded by the presence of Hb caused by hemolysis.
Materials and methods

Protein expression
The plasmid encoding IsdH N1N2N3 (amino acid residues 82-655) was described earlier [16] here we introduced the Y642A mutation previously described [20] and DNA encoding the amino acid sequence GSGSGSC at the C-terminus enabling site specific conjugation. The protein was expressed and purified as described in [16] .
Coupling of Sepharose
Thiopropyl Sepharose (GE Lifesciences, Brondby, Denmark) was conjugated with IsdH-C according to the manufacturer's instruction, details can be found in the Supplementary section.
Bio-Layer Interferometry on IsdH-C binding to Hb-Hp
BLI measurements were performed on Octet RED96e (FortéBio/Molecular Devices) with biotinylated IsdH or IsdH-C immobilized on the chip. Details can be found in the Supplementary section.
Plasma samples and hemolysate
For experiments with spiked plasma and serum, whole blood from three healthy volunteers (one of each phenotype Hp1-1, Hp2-1 and Hp2-2) was drawn in lithium (Li) heparin tubes, sodium citrate tubes, K 2 EDTA tubes and serum tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Serum was allowed to clot for 60 min. All tubes were centrifuged at 1912 g for 7 min at room temperature and plasma or serum was isolated. Hemolysate was prepared by mixing one volume of the erythrocyte fraction from the Li-heparin tubes, with two volumes 0.9% saline and exposing the mixture to four freezethaw cycles. The Hb concentration in the hemolysate was measured using a Sysmex XN-10 analyzer (Sysmex Corporation, Kobe, Japan).
For experiments with patient samples, nine anonymized Liheparin plasma samples with apparent moderate or high degree of hemolysis were collected and subsequently had their H-indices and selected plasma parameters measured on the Cobas 8000 c702 and e801 systems (Roche Diagnostics, Mannheim, Germany).
For the plasma and serum Hb-spiking experiments samples were obtained and analyzed from healthy volunteer donors in accordance with Danish law and internal guidelines. For the analysis of patient samples, anonymized end-of-life samples were used in accordance with Danish law and internal guidelines.
Hemoglobin binding capacity of IsdH-C Sepharose
Plasma samples from healthy volunteers (Hp1-1, Hp2-1 and Hp2-2) were spiked with increasing amounts of hemolysate corresponding to final Hb concentrations of 2.5, 5, 7.5, 10.0, 12.5, 15.0 and 20.0 mg/mL. A volume of 200 μL IsdH-C Sepharose or sham Sepharose slurry (1:1 PBS and Sepharose) was added to an Eppendorf tube and centrifuged at 1000 g for 5 min. The PBS was removed to minimize dilution. A volume of 100 μL Hb spiked plasma was added to the tubes with IsdH-C Sepharose or sham Sepharose (1:1 Sepharose and plasma) and the mixtures were incubated 30 min with gentle rotation. The samples were centrifuged at 1000 g for 5 min and the plasma fraction was used for H-index analysis. In parallel, samples were treated with HemogloBind (Biotech Support Group, Monmouth Junction, USA) according to the manufacturer's protocol.
Measurement of hemoglobin sensitive analytes in hemolyzed plasma samples
Hp2-1 plasma from a healthy volunteer was spiked with hemolysate to a concentration of 3 mg/mL Hb. Volumes of 500 μL spiked plasma were treated with IsdH-C Sepharose, sham Sepharose (1:2 Sepharose and plasma) or HemogloBind as described. A similar procedure was used for the hemolyzed patient plasma.
Assays were chosen based on a high Hb sensitivity on the Cobas 8000 c702 and e801 systems (Roche Diagnostics, Mannheim, Germany) ( Table 1 ). The assays for ALB, Ca and thyrotropin were considered non-sensitive to hemolysis based on the high threshold of 10 mg/mL Hb on the Cobas 8000 system. All analyses were performed by laboratory technicians on the Cobas 8000 system using the newest assay applications. Regarding the patient plasma, only ALB, ALP, BILI-C, CK and Ferri were measured due to scarce amounts of plasma. Calculations of degree of dilution after adding of IsdH-C Sepharose, sham Sepharose or HemogloBind were based on comparison of ALB before and after treatment. The calculated degrees of dilution were 1.4 for IsdH-C Sepharose, 1.6 for sham Sepharose and 2.1 for HemogloBind. The measured concentrations of analytes were adjusted for the degree of dilution.
Western blot
Plasma samples were diluted 1:125 in 0.9% NaCl and purified Hp2-2 and Hp1-1 (Sigma-Aldrich) were diluted to 7.7 μg/mL in 0.9% NaCl to be used as positive controls. Samples were run on a 3%-8% tris-acetate gel (Invitrogen, Taastrup, Denmark) in Tris-acetate buffer and blotted on PVDF membranes. Membranes were blocked in 5% skimmed milk in wash buffer (PBS with 0.05% tween 20), followed by incubation with polyclonal rabbit anti-human haptoglobin (A0030; DAKO, Roskilde, Denmark) diluted 1:1000 in wash buffer with 1% skimmed milk. The membrane was washed 3 × 5 min and incubated with polyclonal goat anti-rabbit HRP (P0448; DAKO) diluted 1:2000 as secondary antibody in wash buffer with 1% skimmed milk. After 3 × 5 min of washing, the membranes were developed using SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo Scientific).
Results
Development of a high-affinity high-capacity hemoglobin-binding matrix
The Hb-binding IsdH variant, designated IsdH-C, containing amino acid residues 82-655 of IsdH was genetically engineered by the introduction of a C-terminal cysteine in the recombinant protein to allow covalent conjugation with optimal spatial orientation of the protein to thiopropyl Sepharose ( Figure 1A ). Furthermore, an amino acid substitution (Y642A) in the heme-extracting domain N3 ( Figure 1A ) was introduced to prevent undesirable IsdHmediated extraction of heme from Hb present in a sample.
This construct has the same affinity for Hb and Hb-Hp as wild type IsdH, as confirmed by Bio-Layer Interferometry (BLI) analysis ( Figure 1B ).
Clearance of plasma and serum samples spiked with hemoglobin
Li-heparin plasma samples from Hp1-1, Hp2-1 and Hp2-2 individuals were spiked with increasing amounts of Hb-containing hemolysate followed by treatment with IsdH-C Sepharose to remove the added Hb. Corresponding experiments were conducted using sham Sepharose, without the IsdH-C protein, and the commercial Hb removal matrix HemogloBind. The data revealed that IsdH-C Sepharose was by far the most effective matrix for Hb removal. For all three Hp phenotypes, only IsdH-C Sepharose was able to completely clear samples and did so up to 12.5 mg/mL Hb. Neither sham Sepharose nor HemogloBind were able to completely clear the samples from Hb at any concentration (Figure 2A ). The effect of GGt  2  Iron  Fe  2  Thyroxine total T4  TT4  2.3  Thyrotropine  TSH  10  Troponine T  TNT  1 The Hb sensitivity of the assays (according to the manufacturer, Roche) used in this study.
Hb removal was also visually evident ( Figure 2B ). Furthermore, the hemoglobin removal capacities were similar in Hb spiked Li-heparin plasma, EDTA plasma, sodium citrate plasma and serum (Figure 3 ). Hb binds Hp with high affinity and IsdH binds both Hb and the Hb-Hp complex, but not Hp alone [16] . Only IsdH-C Sepharose was able to clear Hp from Hb-spiked plasma (Figure 4) , where only faint Hp bands were visible in western blots from these samples. This shows that Hb-Hp was removed from the samples, whereas Hemo-gloBind seemed unable to bind Hb complexed to Hp. Minor amounts of multimers of Hp2-2 were still present in spiked plasma after treating the Hb-spiked samples with IsdH-C Sepharose even at Hb concentration sufficient to saturate Hp.
Measurement of hemoglobin sensitive analytes in plasma samples spiked with hemoglobin
H-index data from of 27,312 anonymized plasma samples analyzed during a period of 10 days in a large routine biochemical laboratory showed the typical range of hemolysis levels. Within the 99.99% percentile the maximal level of hemolysis was 4.05 mg/mL Hb ( Table 2 ). For further analysis 3.00 mg/mL Hb was chosen as a realistic hemolysis degree in the high end of the 10-day survey and classified as moderate degree of hemolysis [21] .
Analysis of a range of parameters was not possible in the hemolysate-spiked samples due to the high H-index. IsdH-C Sepharose was superior in lowering the H-index in these spiked samples ( Figure 5J ) compared to sham Sepharose and HemogloBind.
After Hb removal using IsdH-C Sepharose, eliminating the interference by Hb, several parameters could now be determined and found to be comparable to the levels in unspiked plasma ( Figure 5 ). In general, for routine determination of analytes in plasma a deviation below 10% from the baseline plasma value, due to interference, is acceptable [11, 22] . When comparing the parameters measured in the Hb cleared plasma samples, IsdH-C Sepharose was superior to HemogloBind in restoring values corresponding to values in unspiked plasma. IsdH-C Sepharose enabled the correct measurement of BILI-C, Fe, Ferri, TnT, TT4, GTT and ALP by restoring their measured level to be below 10% deviation from the unspiked plasma value, while HemogloBind only restored measurement of CK, GTT and ALP to come within a 10% deviation from unspiked plasma ( Figure 5 ).
Furthermore, when subjecting unspiked plasma to the matrices, it was observed that HemogloBind severely affected the measurement of the hemolysis insensitive analytes thyrotropin (TSH) and calcium (Ca) (Supplementary Material, Figure S1 ), which became barely detectable, indicating that these analytes may bind to the HemogloBind matrix. It was not possible to measure TnT in the Hemo-gloBind treated sample, probably due to dilution below the limit of detection or binding of TnT to the matrix. The low levels of AmylP measured in IsdH-C treated samples is likely due to unspecific binding of AmylP to the Sepharose matrix, as this effect is seen for both IsdH-C Sepharose and the sham Sepharose ( Figure 5 ).
Clearance of hemoglobin and measurement of hemoglobin-sensitive analytes in hemolyzed plasma samples from patients
Plasma samples with moderate to high degree of hemolysis were obtained from nine anonymized patients without known causes of hemolysis. The measured Hb concentration in the plasma samples ranged from 0.56 to 3.42 mg/mL Hb. For all nine patient samples, IsdH-C Sepharose lowered the Hb concentration substantially compared to sham Sepharose or HemogloBind ( Figure 6A) . It was subsequently possible to measure the analytes ALP, BILI-C, CK and Ferri (measured levels not shown) and the treatment with IsdH-C Sepharose significantly reduced the number of error messages automatically generated due to hemolysis compared to the untreated plasma (Table 3) . Similar to the observation in Figure 4 with the Hb spiked plasma samples, IsdH-C Sepharose was able to remove Hb bound to Hp from the patient samples, while this was not the case for sham Sepharose or HemogloBind ( Figure 6B ).
Discussion
By exploiting the high affinity of the bacterial IsdH protein for Hb and Hb-Hp, we have developed a method based on IsdH-C Sepharose for removing Hb from serum and plasma, enabling the correct analysis of a range of parameters in hemolyzed blood samples. Further, the IsdH-C Sepharose is overall superior to the commercial product HemogloBind that has been claimed as an Hb-removing compound.
Our results show that IsdH-C Sepharose efficiently clears high amounts of Hb from plasma spiked with hemolysate and that several hemolysis-sensitive blood analyses (ALP, BILI-C, Fe, Ferri, GGT, TT4 and TnT) are correctly measured (within 10% deviation) after Hbclearance. IsdH-C Sepharose was also able to remove significant amounts of Hb from hemolyzed plasma from anonymized patients thus decreasing the number of error messages related to hemolysis. Importantly, IsdH-C Sepharose binds both free Hb and Hb in complex with Hp [15, 16] in contrast to HemogloBind that does not bind the Hb-Hp complex. HemogloBind binds Hb unspecifically by a combination of its polymer composition, charge properties and cross-linking architecture [23] . Apparently, the physiochemical properties of Hb and Hb-Hp causes HemogloBind to preferentially bind Hb and not Hb-Hp, as shown in western blots of HemogloBind-treated plasma samples and also reported previously [24] .
IsdH-C Sepharose is superior to the commercial product HemogloBind in several ways: less dilution of the sample, less parameters affected by unspecific binding, and a more efficient Hb removal including binding of Hp-Hb complexes. The latter seems as a major factor explaining why IsdH-C Sepharose is more efficient than HemogloBind in clearing Hb.
A low level of Hp is a marker of in vivo hemolysis, concurrently, it is important also to measure Hp in the untreated plasma sample, to detect if the hemolysis is of in vivo origin. In the case of in vitro hemolysis, resampling may be an option for performing analysis sensitive to Hb. However, resampling is time and cost consuming, and for urgent analysis it may not be an attractive option. For example, in a patient suspected of myocardial infarction time is of the essence and minimizing the delay on TnT results is essential.
For patients with fragile erythrocytes and/or persistent in vivo hemolysis, sampling plasma without Hb is inherently impossible, and a number of important blood parameters cannot be measured without the removal of Hb from the sample. For instance, it may be difficult to measure (1) a compromised liver function in septic patients due to Hb interference of ALP and bilirubin, (2) iron overload in children with hemochromatosis due to Hb interference of Fe and Ferri and (3) to diagnose a myocardial infarction in hemolytic patients with malignant myeloid conditions. In patients with persistent hemolysis Hp may be saturated with Hb and depleted, leading to partly degradation of free Hb. Heme may then not only be found bound to Hb but also free or bound to hemopexin or albumin, the complex of heme-hemopexin being cleared by lowdensity lipoprotein receptor-related protein [25] . IsdH will not be able to bind these heme species, and in these cases removal of all Hb-derived heme from a sample may not be facilitated by IsdH.
In our view IsdH-C Sepharose or an alternative IsdH-C matrix has the potential to be used in an automated set-up for removal of Hb from hemolyzed blood samples. Furthermore, IsdH-mediated removal of Hb may be used within research to rescue hemolyzed samples from animal or clinical studies where resampling is not an option.
To ease integration in an automated system, centrifugation should be avoided, and the level of dilution and unspecific binding to the matrix should ideally also be reduced. This could be accomplished by exchanging the Sepharose matrix with another surface, such as magnetic beads or a plastic surface. In an integrated setup, a plasma sample will be analyzed for hemolysis, should there be hemolysis, the sample will be divided in two, one part for testing Hb-insensitive parameters and another part from which Hb is removed using, e.g. magnetic beads with IsdH-C followed by determination of Hb-sensitive parameters. Further studies are needed to determine the full scope of Hb sensitive assays on different analytical platforms in which IsdH mediated Hb removal can enable analysis and the ideal matrix for IsdH-C to ease integration into an automated setup.
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